Kemal dedeman kimdir
Share your interactive ePaper on all platforms and on your website with our embed function. One of the quintessential elements of Turkish - Dedeman.
Federal government websites often end in. The site is secure. To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy CRT followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer NSCLC. Ninety three patients were included in this retrospective study. Median age of the patients was 57 range, The median follow-up was 13 months range: months. Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC.
Kemal dedeman kimdir
Sign in. Current issue Archive Contemporary Oncology Search. Send email. Copy url:. Celalettin Eroglu. Dilek Unal. Neslihan Kurtul. Ummuhan Abdulrezzak. Koray Gumu. PlumX metrics:. Introduction Choroidal metastasis is the most common intraocular malignancy in adults [1—3].
However, it cannot certainly differentiate between the primary tumour and metastasis [10].
.
İnternet sitesi. This site uses Akismet to reduce spam. Learn how your comment data is processed. Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website. İlgili Makaleler. Facebook Twitter WhatsApp Telegram.
Kemal dedeman kimdir
.
Hsr empire hotel
Two amelanositic lesions in the upper temporal area in the right eye were detected during examination of the eyes. Authors declare no conflict of interest. Celalettin Eroglu. E-mail: moc. J Natl Cancer Inst. Cookie settings. Treatment characteristics was shown in Table 2. Flag as Inappropriate Cancel. Copy url:. Predictors of survival in patients with non-small cell lung cancer. References 1. Staging work-up included chest plain radiographs, computed tomography scan of the chest and abdomen in some cases abdominal sonography , magnetic resonance imaging of the brain, radionuclide bone scan, bronchofiberscopy, and mediastinoscopy. For every patient, a dose density was calculated from the scheduled dose and the dose applied.
.
Journals Books eBooks Events. Main languages. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Survival data The median follow-up was 13 months range: months. Response time was defined in patients who were detected complete and PR as the time, which from 1 st month after CRT until to progression of disease or to death. Figure 1. Received Sep 24; Accepted Jan Consolidation chemotherapy was administered for a median of four cycles range: Share from page:. Utility of positron emission tomography in pediatric oncology. When we compared our sample size with previous studies, we saw that we had a larger sample size except the study of Segawa et al. We think that, consolidation chemotherapy with 4 cycles docetaxel plus cisplatin after concurrent CRT with the same agents could not show survival advantage according to usage of fewer chemotherapy cycles or not. That's why we decided not to routinely give consolidation chemotherapy to all patients. Survival after the development of orbital metastasis is poor [9].
Bravo, what necessary phrase..., a remarkable idea
Willingly I accept. An interesting theme, I will take part.
Really and as I have not guessed earlier